A randomized open-label clinical trial of an anti-HPV biological dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection

Currently, there is no specific antiviral therapy for HPV infection. We conducted a randomized open-label clinical trial of JB01-BD, an anti-HPV biological dressing from Shanxi Jinbo Pharmaceutical Co., Ltd., China, for treatment of HPV infection. Seventy-seven women with cervical infection by high-risk HPV were randomly divided into a treatment group and a non-treatment group. After treatment, about 60.5% (23/38) of HPV-positive women in the treatment group became HPV-negative compared with 13.5% (5/37) of women in the non-treatment group becoming HPV-negative (P < 0.001). These data suggest that JB01-BD is an effective topical biological agent for the treatment of cervical HPV infection.